This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by James, R. A. Articles by Ridgway, E. C. Search for Related Content PubMed PubMed Citation Articles by James, R. A. Articles by Ridgway, E. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LEVOTHYROXINE

Thyroid Hormone-Induced Expression of Specific Somatostatin Receptor Subtypes Correlates with Involution of the TtT-97 Murine Thyrotrope Tumor¹

Department of Medicine, Division of Endocrinology, University of Colorado Health Science Center (R.A.J., V.D.S., J.M.D., D.F.G., W.M.W., E.C.R.), Denver, Colorado 80262; Sandoz Pharma (C.B., F.R.), Basel, Switzerland; and the Department of Medicine, Division of Endocrinology, University, of Newcastle-upon-Tyne (R.A.J.), Newcastle-upon-Tyne, United Kingdom

Address all correspondence and requests for reprints to: Dr. William M. Wood, Department of Medicine, Division of Endocrinology, Campus Box B151, University of Colorado Health Science Center, 4200 East Ninth Avenue, Denver, Colorado 80262. E-mail: Andy.James{at}btinternet.com

Following the protracted hypothyroid state, treatment with thyroid hormone will induce a decline in TSH and reduce thyrotrope hyperplasia. Somatostatin is a hypothalamic peptide that has been implicated in the negative regulation of TSH secretion in the thyrotrope. Moreover, analogs of native somatostatin have potent TSH-reducing and growth-retarding effects on human thyrotropinomas. The TtT-97 tumor is an in vivo murine thyrotropic model that has retained its physiological response to thyroid hormone. This study investigates the regulation of somatostatin receptor subtypes in this tumor. TtT-97 tumors, actively growing in hypothyroid mice, did not express any significant somatostatin receptor messenger RNA (mRNA) or protein. T₄ administration resulted in a reduction in TSHß mRNA expression and a marked degree of tumor involution. Analysis of residual tumors from thyroid hormone-treated mice showed the specific up-regulation of SSTR1 and SSTR5 mRNA subtypes and the appearance of abundant, high affinity SSTR receptor-binding sites within the tumor. Thus, the TtT-97 tumor provides a thyrotrope-specific model in which to study the regulation of somatostatin receptor subtypes by thyroid hormone and correlate this expression with both antisecretory and antiproliferative effects.

This article has been cited by other articles:

				L. E. Nelson and M. A. Sheridan Insulin and growth hormone stimulate somatostatin receptor (SSTR) expression by inducing transcription of SSTR mRNAs and by upregulating cell surface SSTRs Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2006; 291(1): R163 - R169. [Abstract] [Full Text] [PDF]

				W. W. Woodmansee, J. M. Kerr, E. A. Tucker, J. R. Mitchell, D. J. Haakinson, D. F. Gordon, E. C. Ridgway, and W. M. Wood The Proliferative Status of Thyrotropes Is Dependent on Modulation of Specific Cell Cycle Regulators by Thyroid Hormone Endocrinology, January 1, 2006; 147(1): 272 - 282. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				S. Petersenn, A. C. Rasch, C. Bohnke, and H. M. Schulte Identification of an Upstream Pituitary-Active Promoter of Human Somatostatin Receptor Subtype 5 Endocrinology, July 1, 2002; 143(7): 2626 - 2634. [Abstract] [Full Text] [PDF]

				W. W. Woodmansee, R. L. Mouser, D. F. Gordon, J. M. Dowding, W. M. Wood, and E. C. Ridgway Mutational Analysis of the Mouse Somatostatin Receptor Type 5 Gene Promoter Endocrinology, June 1, 2002; 143(6): 2268 - 2276. [Abstract] [Full Text] [PDF]

				A. Spada and P. Beck-Peccoz Editorial: New Strategy to Solve the Etiopathogenetic Conundrum of Pituitary Adenomas Endocrinology, February 1, 2002; 143(2): 343 - 346. [Full Text] [PDF]

				W. M. Wood, V. D. Sarapura, J. M. Dowding, W. W. Woodmansee, D. J. Haakinson, D. F. Gordon, and E. C. Ridgway Early Gene Expression Changes Preceding Thyroid Hormone-Induced Involution of a Thyrotrope Tumor Endocrinology, February 1, 2002; 143(2): 347 - 359. [Abstract] [Full Text] [PDF]

				M. L. Brinkmeier, J. H. Stahl, D. F. Gordon, B. D. Ross, V. D. Sarapura, J. M. Dowding, S. K. Kendall, R. V. Lloyd, E. C. Ridgway, and S. A. Camper Thyroid Hormone-Responsive Pituitary Hyperplasia Independent of Somatostatin Receptor 2 Mol. Endocrinol., December 1, 2001; 15(12): 2129 - 2136. [Abstract] [Full Text] [PDF]

				D. F. Gordon, W. W. Woodmansee, S. R. Lewis, R. A. James, W. M. Wood, and E. C. Ridgway Cloning of the Mouse Somatostatin Receptor Subtype 5 Gene: Promoter Structure and Function Endocrinology, December 1, 1999; 140(12): 5598 - 5608. [Abstract] [Full Text]

				S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]